ID

38232

Descrizione

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01045304

collegamento

https://clinicaltrials.gov/show/NCT01045304

Keywords

versioni (1)
  1. 30/09/19 30/09/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

30 settembre 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Cancer, Metastatic NCT01045304

Inglese

Eligibility Breast Cancer, Metastatic NCT01045304

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically documented breast cancer (either primary or metastatic site) that is er (estrogen receptor)-negative, pgr (progesterone receptor)-negative ( <10% tumor staining by immunohistochemistry [ihc]) and her2 (human epidermal growth factor 2) non-overexpressing by ihc (0,1+) or, ihc 2+ and fish (fluorescence in situ hybridization) negative.
Descrizione

Breast Carcinoma Primary tumor site | Secondary malignant neoplasm of female breast | Estrogen receptor negative Immunohistochemistry | Progesterone receptor negative Immunohistochemistry | HER2 Protein Overexpression Absent Immunohistochemistry | HER2 Protein Overexpression Absent FISH Negative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0678222
UMLS CUI [1,2]
C0475447
UMLS CUI [2]
C0346993
UMLS CUI [3,1]
C0279756
UMLS CUI [3,2]
C0021044
UMLS CUI [4,1]
C0279766
UMLS CUI [4,2]
C0021044
UMLS CUI [5,1]
C1515560
UMLS CUI [5,2]
C0332197
UMLS CUI [5,3]
C0021044
UMLS CUI [6,1]
C1515560
UMLS CUI [6,2]
C0332197
UMLS CUI [6,3]
C0162789
UMLS CUI [6,4]
C1513916
metastatic breast cancer with measurable disease by the revised guideline for response evaluation criteria in solid tumors version 1.1 (recist 1.1 criteria);
Descrizione

Secondary malignant neoplasm of female breast | Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0346993
UMLS CUI [2]
C1513041
prior treatment that includes:
Descrizione

Prior Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1514463
never having received anticancer therapy for metastatic disease or
Descrizione

Cancer treatment Absent Neoplasm Metastasis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0027627
having received 1 or 2 prior chemotherapy regimens in the metastatic setting (prior neo-adjuvant/adjuvant systemic therapy is considered as a prior chemotherapy if the first relapse occurred less than one year after the last treatment administration).
Descrizione

Prior Chemotherapy Quantity Neoplasm Metastasis | Neoadjuvant Therapy Systemic | Adjuvant therapy Systemic

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0027627
UMLS CUI [2,1]
C0600558
UMLS CUI [2,2]
C0205373
UMLS CUI [3,1]
C0677850
UMLS CUI [3,2]
C0205373
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with gemcitabine, carboplatin, cisplatin or any parp inhibitor;
Descrizione

gemcitabine | Carboplatin | Cisplatin | PARP Inhibitors

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0045093
UMLS CUI [2]
C0079083
UMLS CUI [3]
C0008838
UMLS CUI [4]
C1882413
bone metastasis as only disease location (except for bone metastasis with measurable soft tissue component);
Descrizione

Secondary malignant neoplasm of bone | Disease Location only | Exception Soft tissue Component Measurable

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0153690
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C1515974
UMLS CUI [2,3]
C0205171
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0225317
UMLS CUI [3,3]
C1705248
UMLS CUI [3,4]
C1513040
major medical conditions that might affect study participation e.g., uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease.
Descrizione

Medical condition Major Affecting Study Subject Participation Status | Pulmonary Dysfunction Uncontrolled | Renal dysfunction Uncontrolled | Liver Dysfunction Uncontrolled | Communicable Disease Uncontrolled | Heart Disease Uncontrolled

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0205164
UMLS CUI [1,3]
C0392760
UMLS CUI [1,4]
C2348568
UMLS CUI [2,1]
C1709770
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C3279454
UMLS CUI [3,2]
C0205318
UMLS CUI [4,1]
C0086565
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0009450
UMLS CUI [5,2]
C0205318
UMLS CUI [6,1]
C0018799
UMLS CUI [6,2]
C0205318
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Descrizione

Study Subject Participation Status | Considerations Additional

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0518609
UMLS CUI [2,2]
C1524062
Ritorna all'inizio della pagina

Similar models

Eligibility Breast Cancer, Metastatic NCT01045304

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Breast Carcinoma Primary tumor site | Secondary malignant neoplasm of female breast | Estrogen receptor negative Immunohistochemistry | Progesterone receptor negative Immunohistochemistry | HER2 Protein Overexpression Absent Immunohistochemistry | HER2 Protein Overexpression Absent FISH Negative
Item
histologically documented breast cancer (either primary or metastatic site) that is er (estrogen receptor)-negative, pgr (progesterone receptor)-negative ( <10% tumor staining by immunohistochemistry [ihc]) and her2 (human epidermal growth factor 2) non-overexpressing by ihc (0,1+) or, ihc 2+ and fish (fluorescence in situ hybridization) negative.
boolean
C0678222 (UMLS CUI [1,1])
C0475447 (UMLS CUI [1,2])
C0346993 (UMLS CUI [2])
C0279756 (UMLS CUI [3,1])
C0021044 (UMLS CUI [3,2])
C0279766 (UMLS CUI [4,1])
C0021044 (UMLS CUI [4,2])
C1515560 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0021044 (UMLS CUI [5,3])
C1515560 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
C0162789 (UMLS CUI [6,3])
C1513916 (UMLS CUI [6,4])
Secondary malignant neoplasm of female breast | Measurable Disease
Item
metastatic breast cancer with measurable disease by the revised guideline for response evaluation criteria in solid tumors version 1.1 (recist 1.1 criteria);
boolean
C0346993 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
Prior Therapy
Item
prior treatment that includes:
boolean
C1514463 (UMLS CUI [1])
Cancer treatment Absent Neoplasm Metastasis
Item
never having received anticancer therapy for metastatic disease or
boolean
C0920425 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Prior Chemotherapy Quantity Neoplasm Metastasis | Neoadjuvant Therapy Systemic | Adjuvant therapy Systemic
Item
having received 1 or 2 prior chemotherapy regimens in the metastatic setting (prior neo-adjuvant/adjuvant systemic therapy is considered as a prior chemotherapy if the first relapse occurred less than one year after the last treatment administration).
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C0600558 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0677850 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
gemcitabine | Carboplatin | Cisplatin | PARP Inhibitors
Item
prior treatment with gemcitabine, carboplatin, cisplatin or any parp inhibitor;
boolean
C0045093 (UMLS CUI [1])
C0079083 (UMLS CUI [2])
C0008838 (UMLS CUI [3])
C1882413 (UMLS CUI [4])
Secondary malignant neoplasm of bone | Disease Location only | Exception Soft tissue Component Measurable
Item
bone metastasis as only disease location (except for bone metastasis with measurable soft tissue component);
boolean
C0153690 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C1515974 (UMLS CUI [2,2])
C0205171 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0225317 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
C1513040 (UMLS CUI [3,4])
Medical condition Major Affecting Study Subject Participation Status | Pulmonary Dysfunction Uncontrolled | Renal dysfunction Uncontrolled | Liver Dysfunction Uncontrolled | Communicable Disease Uncontrolled | Heart Disease Uncontrolled
Item
major medical conditions that might affect study participation e.g., uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease.
boolean
C3843040 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0392760 (UMLS CUI [1,3])
C2348568 (UMLS CUI [1,4])
C1709770 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C3279454 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0086565 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0009450 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0018799 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
Study Subject Participation Status | Considerations Additional
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
C0518609 (UMLS CUI [2,1])
C1524062 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial